Shares of Vectura Group PLC (LON:VEC) have received a consensus rating of “Buy” from the eleven analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is GBX 210 ($2.71).
A number of research analysts recently weighed in on the company. Shore Capital reissued a “buy” rating on shares of Vectura Group PLC in a report on Wednesday, August 16th. Peel Hunt reaffirmed a “hold” rating and issued a GBX 160 ($2.07) price objective on shares of Vectura Group PLC in a report on Wednesday, August 16th. N+1 Singer reaffirmed a “hold” rating on shares of Vectura Group PLC in a report on Thursday, June 29th. Numis Securities Ltd reissued a “buy” rating on shares of Vectura Group PLC in a report on Monday, May 22nd. Finally, Panmure Gordon reissued a “buy” rating on shares of Vectura Group PLC in a report on Wednesday, August 30th.
Shares of Vectura Group PLC (LON:VEC) traded up 0.29% during trading on Friday, reaching GBX 103.80. The company’s stock had a trading volume of 2,136,859 shares. The company’s market cap is GBX 704.28 million. The stock’s 50 day moving average price is GBX 108.38 and its 200 day moving average price is GBX 126.12. Vectura Group PLC has a 52 week low of GBX 88.90 and a 52 week high of GBX 166.97.
COPYRIGHT VIOLATION WARNING: This article was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/09/16/vectura-group-plc-vec-given-consensus-recommendation-of-buy-by-brokerages.html.
In other Vectura Group PLC news, insider Bruno Angelici bought 70,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was acquired at an average price of GBX 99 ($1.28) per share, with a total value of £69,300 ($89,500.19). Also, insider Andrew Derodra bought 82,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were acquired at an average cost of GBX 90 ($1.16) per share, with a total value of £73,800 ($95,311.89). In the last three months, insiders bought 152,293 shares of company stock valued at $14,339,837.
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.